Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States

Pediatrics

Volumn 125, Issue 2, 2010, Pages

  Wang, Florence T ^a   Mast, T Christopher ^b   Glass, Roberta J ^a   Loughlin, Jeanne ^a   Seeger, John D ^a,c  

^a Department of Epidemiology ^*  (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Gastroenteritis; Immunization; Rotavirus vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; PENTAVALENT ROTAVIRUS VACCINE; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

ACUTE GASTROENTERITIS; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DIPHTHERIA; DRUG EFFICACY; EMERGENCY WARD; FEMALE; GASTROENTERITIS; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL COST; HOSPITALIZATION; HUMAN; IMMUNIZATION; INFANT; LICENSING; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PERTUSSIS; PHYSICIAN; PRIORITY JOURNAL; PUBLIC HEALTH; RISK REDUCTION; ROTAVIRUS; ROTAVIRUS GASTROENTERITIS; TETANUS; TREATMENT OUTCOME; UNITED STATES; VIRUS INFECTION;

DATABASES, FACTUAL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; EMERGENCY MEDICAL SERVICES; FEMALE; GASTROENTERITIS; HOSPITALIZATION; HUMANS; INFANT; MALE; PRODUCT SURVEILLANCE, POSTMARKETING; RETROSPECTIVE STUDIES; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, ATTENUATED;

EID: 76049114803     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2009-1246     Document Type: Article

References (15)

1. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis. 2003;9(5):565-572
2. Tucker AW, Haddix AC, Bresee JS, et al. Cost-effectiveness analysis of a rotavirus immunization program in the United States. JAMA. 1998;279(17):1371-1376
3. Widdowson MA, Meltzer MI, Zhang X, et al. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics. 2007;119(4):684-697
4. Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-12):1-13
5. Griffin DD, Kirkwood CD, Parashar UD, et al. Surveillance of rotavirus strains in the United States: identification of unusual strains. J Clin Microbiol. 2000;38(7):2784-2787
6. Abdel-Haq NM, Thomas RA, Asmar BI, et al. Increased prevalence of G1P[4] genotype among children with rotavirus-associated gastroenteritis in metropolitan Detroit. J Clin Microbiol. 2003;41(6):2680-2682
7. Merck. RotaTeq [package insert]. Whitehouse Station, NJ: Merck; 2007
8. Vesikari T, Matson DO, Dennehy P, et al. Safety and effectiveness of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23-33
9. Centers for Disease Control and Prevention. National Respiratory and Enteric Virus Surveillance System: rotavirus surveillance: trends in the U.S. Available at: www.cdc.gov/surveillance/nrevss/rotavirus/natl-trend.html. Accessed December 3, 2009
10. Ewell M. Comparing methods for calculating confidence intervals for vaccine efficacy. Stat Med. 1996;15(21-22):2379-2392
11. Centers for Disease Control and Prevention. Delayed onset and diminished magnitude of rotavirus activity: United States, November 2007-May 2008. MMWR Morb Mortal Wkly Rep. 2008;57(25):697-700
12. Clark HF, Lawley D, Mallette LA, DiNubile MJ, Hodinka RL. Decline in cases of rotavirus gastroenteritis presenting to the Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine. Clin Vaccine Immunol. 2009;16(3):382-386
13. Mast TC, Wang FT, Goli V, Loughlin J, Bulotsky B, Seeger JS. Post-licensure effectiveness of RotaTeq in preventing gastroenteritis. Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) 46th Annual Meeting; October 25-28, 2008; Washington, DC
14. Hsu VP, Staat MA, Roberts N, et al. Use of active surveillance to validate International Classification of Diseases code estimates of rotavirus hospitalizations in children. Pediatrics. 2005;115(1):78-82
15. Patel MM, Tate JE, Selvarangan R, et al. Routine laboratory testing data for surveillance of rotavirus hospitalizations to evaluate the impact of vaccination. Pediatr Infect Dis J. 2007;26(10):914 -919